<DOC>
	<DOCNO>NCT01001377</DOCNO>
	<brief_summary>The primary objective study compare effect panitumumab versus cetuximab overall survival ( OS ) chemorefractory metastatic colorectal cancer ( mCRC ) among patient wild-type Kirsten rat Sarcoma-2 virus ( KRAS ) tumor .</brief_summary>
	<brief_title>ASPECCT : A Study Panitumumab Efficacy Safety Compared Cetuximab Patients With KRAS Wild-Type Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis adenocarcinoma colon rectum , metastatic disease Wildtype KRAS tumor status Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 2 Must fail prior regimen contain irinotecan metastatic disease prior regimen contain oxaliplatin metastatic disease Must previously receive thymidylate synthase inhibitor ( eg , fluorouracil , capecitabine , raltitrexed , fluorouraciluracil ) point treatment colorectal cancer ( CRC ) Adequate hematologic , renal , hepatic metabolic function Symptomatic brain metastasis require treatment Prior antiepidermal growth factor receptor ( EGFr ) antibody therapy ( eg , panitumumab cetuximab ) treatment small molecule EGFr inhibitor ( eg , gefitinib , erlotinib , lapatinib ) Antitumor therapy ( eg , chemotherapy , hormonal therapy , immunotherapy , antibody therapy , radiotherapy ) , investigational agent therapy ≤ 30 day randomization . Clinically significant cardiovascular disease Active infection require systemic treatment uncontrolled infection ≤14 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Erbitux</keyword>
	<keyword>Metastatic</keyword>
</DOC>